Skip to main content
. 2014 Dec 1;11:39. doi: 10.1186/1742-6405-11-39

Figure 2.

Figure 2

Efficacy through 48 weeks in the overall population. (a) Proportions of viral load responders (<50 copies/ml: FDA snapshot analysis) through 48 weeks (N =313); (b) Median (range) change in CD4+ cell count (cells/mm3) from baseline through 48 weeks (missing = excluded).